BridgeBio Pharma, Inc., 10% Owner at Eidos Therapeutics, Inc. (EIDX), bought 1,764,706 shares at $29.90 ($52.8M) on 2019-07-03, disclosed to the SEC on 2019-07-08.
Open-market purchase of $52.8M EIDX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.90 | 882,353 | $26.4M | 50.0% |
| 2 | $29.90 | 882,353 | $26.4M | 50.0% |
| Total | $29.90 avg | 1,764,706 | $52.8M | 100% |